Author: Okba, Nisreen MA; Raj, V Stalin; Haagmans, Bart L
Title: Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches Cord-id: w1l8h8g8 Document date: 2017_4_13
ID: w1l8h8g8
Snippet: Middle East respiratory syndrome coronavirus (MERS-CoV) is a cause of severe respiratory infection in humans, specifically the elderly and people with comorbidities. The re-emergence of lethal coronaviruses calls for international collaboration to produce coronavirus vaccines, which are still lacking to date. Ongoing efforts to develop MERS-CoV vaccines should consider the different target populations (dromedary camels and humans) and the correlates of protection. Extending on our current knowle
Document: Middle East respiratory syndrome coronavirus (MERS-CoV) is a cause of severe respiratory infection in humans, specifically the elderly and people with comorbidities. The re-emergence of lethal coronaviruses calls for international collaboration to produce coronavirus vaccines, which are still lacking to date. Ongoing efforts to develop MERS-CoV vaccines should consider the different target populations (dromedary camels and humans) and the correlates of protection. Extending on our current knowledge of MERS, vaccination of dromedary camels to induce mucosal immunity could be a promising approach to diminish MERS-CoV transmission to humans. In addition, it is equally important to develop vaccines for humans that induce broader reactivity against various coronaviruses to be prepared for a potential next CoV outbreak.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and additional region: 1, 2
- acute respiratory syndrome and adenoviral vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome and adjustment need: 1, 2, 3, 4
- acute respiratory syndrome and adjuvant vaccination: 1, 2, 3
- acute respiratory syndrome and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- acute respiratory syndrome and administration site: 1
- acute respiratory syndrome and adoptive transfer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory syndrome and local immune response: 1, 2, 3, 4, 5, 6
- acute respiratory syndrome and low level neutralization: 1
- acute respiratory syndrome and low neutralizing antibody: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory syndrome and lung eliminate: 1
- acute respiratory syndrome and lung immunopathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory syndrome and lung pathological: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62
- adaptive response and administration route: 1, 2, 3
- adaptive response and local immune response: 1, 2, 3
- adaptive response and lung damage: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive response and lung immunopathology: 1, 2
Co phrase search for related documents, hyperlinks ordered by date